Tris Vaughan, an executive at MedImmune, has joined the scientific advisory board of Sphere Fluidics Ltd, a UK developer of single cell analysis systems for drug discovery and development. Dr Vaughan is vice president R&D antibody discovery and protein engineering at MedImmue, the biologics unit of AstraZeneca Plc. Prior to joining MedImmune he was head of external programmes at Cambridge Antibody Technology.
Sphere Fluidics announced the appointment on 13 August 2018.
Copyright 2018 Evernow Publishing Ltd.